The ability to create such vaccines could minimize or eliminate the cold chain requirements for global deployment and mass vaccination programmes with RNA-based vaccines ... Dec 19
Enesi Pharma's Implavax technology platform would try to make the vaccine needle free and thermally stable... Sep 08
-Advertisements-